TBPH Stock Analysis: Theravance Biopharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 877m USD | 12M Return: 50.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.1M
Qual. Beats: 0
Rev. Trend: 93.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Theravance Biopharma (NASDAQ: TBPH) is a U.S.-based biopharmaceutical company incorporated in 2013 and headquartered in South San Francisco that develops and commercializes respiratory and neurology medicines. Its commercial product is YUPELRI, a once-daily nebulized long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Its lead pipeline asset, Ampreloxetine, is an investigational once-daily norepinephrine reuptake inhibitor currently in Phase 3 development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
The company commercializes YUPELRI through a strategic collaboration with Viatris, a common arrangement in the pharmaceutical industry where a larger partner handles manufacturing, distribution, and field sales while the originating company contributes development and royalty rights. As a small-cap healthcare stock (GICS Pharmaceuticals sub-industry), TBPHs value is closely tied to the progression of its late-stage clinical pipeline and the commercial trajectory of its partnered respiratory product.
- YUPELRI sales accelerate with Viatris partnership expansion
- Ampreloxetine Phase 3 results in MSA patients near-term catalyst
- Cash runway tightens amid elevated R&D spending
| Net Income: 114.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.29 > 0.02 and ΔFCF/TA 38.58 > 1.0 |
| NWC/Revenue: 351.5% < 20% (prev 182.0%; Δ 169.5% < -1%) |
| CFO/TA 0.57 > 3% & CFO 268.8m > Net Income 114.5m |
| Net Debt (-250.1m) to EBITDA (142.5m): -1.76 < 3 |
| Current Ratio: 13.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.3m) vs 12m ago 3.16% < -2% |
| Gross Margin: 80.37% > 18% (prev 38.52%; Δ 41.86% > 0.5%) |
| Asset Turnover: 26.91% > 50% (prev 19.00%; Δ 7.91% > 0%) |
| Interest Coverage Ratio: 76.27 > 6 (EBIT TTM 138.7m / Interest Expense TTM 1.82m) |
| A: 0.82 (Total Current Assets 417.6m - Total Current Liabilities 31.8m) / Total Assets 472.3m |
| B: -1.83 (Retained Earnings -864.6m / Total Assets 472.3m) |
| C: 0.34 (EBIT TTM 138.7m / Avg Total Assets 407.9m) |
| D: 1.60 (Book Value of Equity 290.6m / Total Liabilities 181.7m) |
| Altman-Z'' = 3.36 = A |
| DSRI: 0.60 (Receivables 15.6m/15.4m, Revenue 109.8m/65.3m) |
| GMI: 0.48 (GM 38.52% / 80.37%) |
| AQI: 0.12 (AQ_t 0.06 / AQ_t-1 0.46) |
| SGI: 1.68 (Revenue 109.8m / 65.3m) |
| TATA: -0.33 (NI 114.5m - CFO 268.8m) / TA 472.3m) |
| Beneish M = -3.89 (Cap -4..+1) = AAA |
As of July 08, 2026, the stock is trading at USD 17.01 with a total of 889,561 shares traded. Over the past week, the price has changed by -0.29%, over one month by +4.42%, over three months by +2.72% and over the past year by +50.40%.
Current recommended Stop Loss: 16.60 (which is 2.4% or 1.2 ATR below the current price).
Theravance Biopharma has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold TBPH.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.5 | -3% |
P/E Trailing = 7.5919
P/E Forward = 7.9114
P/S = 7.9932
P/B = 3.0204
P/EG = -0.05
Revenue TTM = 109.8m USD
EBIT TTM = 138.7m USD
EBITDA TTM = 142.5m USD
Long Term Debt = 62.5m USD (estimated: total debt 73.3m - short term 10.8m)
Short Term Debt = 10.8m USD (from shortTermDebt, last quarter)
Debt = 113.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 40.5m
Net Debt = -250.1m USD (calculated: Debt 113.8m - CCE 363.9m)
Enterprise Value = 627.4m USD (877.5m + Debt 113.8m - CCE 363.9m)
Interest Coverage Ratio = 76.27 (Ebit TTM 138.7m / Interest Expense TTM 1.82m)
EV/FCF = 4.63x (Enterprise Value 627.4m / FCF TTM 135.4m)
FCF Yield = 21.59% (FCF TTM 135.4m / Enterprise Value 627.4m)
FCF Margin = 123.4% (FCF TTM 135.4m / Revenue TTM 109.8m)
Net Margin = 104.3% (Net Income TTM 114.5m / Revenue TTM 109.8m)
Gross Margin = 80.37% ((Revenue TTM 109.8m - Cost of Revenue TTM 21.5m) / Revenue TTM)
Gross Margin QoQ = 91.88% (prev none%)
Tobins Q-Ratio = 1.33 (Enterprise Value 627.4m / Total Assets 472.3m)
Interest Expense / Debt = 1.60% (Interest Expense 1.82m / Debt 113.8m)
Taxrate = 16.34% (22.4m / 136.9m)
NOPAT = 116.1m (EBIT 138.7m * (1 - 16.34%))
Current Ratio = 12.70 (Total Current Assets 417.6m / Total Current Liabilities 32.9m)
Debt / Equity = 0.39 (Debt 113.8m / totalStockholderEquity, last quarter 290.6m)
Debt / EBITDA = -1.76 (Net Debt -250.1m / EBITDA 142.5m)
Debt / FCF = -1.85 (Net Debt -250.1m / FCF TTM 135.4m)
Total Stockholder Equity = 261.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 28.08% (Net Income 114.5m / Total Assets 472.3m)
RoE = 43.85% (Net Income TTM 114.5m / Total Stockholder Equity 261.2m)
RoCE = 42.85% (EBIT 138.7m / Capital Employed (Equity 261.2m + L.T.Debt 62.5m))
RoIC = 26.03% (NOPAT 116.1m / Invested Capital 445.8m)
WACC = 7.67% (E(877.5m)/V(991.3m) * Re(8.49%) + D(113.8m)/V(991.3m) * Rd(1.60%) * (1-Tc(0.16)))
Discount Rate = 8.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 1.66%
[DCF] Terminal Value 75.44% ; FCFF base≈135.4m ; Y1≈136.0m ; Y5≈144.1m
[DCF] Fair Price = 48.06 (EV 2.24b - Net Debt -250.1m = Equity 2.49b / Shares 51.8m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.21 | # QB: 0
Revenue Correlation: 93.00 | Revenue CAGR: 28.88% | SUE: 0.06 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=-69.57% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.20 | Chg30d=-37.50% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.21 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+241.8% | GrowthRev=-21.7%
EPS next Year (2027-12-31): EPS=1.25 | Chg30d=+0.00% | Revisions=+50% | GrowthEPS=+497.6% | GrowthRev=+15.1%
[Analyst] Revisions Ratio: +50% (up=3, down=0)